Njood A Alshowigi¹, Mashael A Aluraifej², Najla A Almarshad³, Saleh A Alshowigi⁴, Tarik Alsaid¹, Shahad Alwathnani1 and Mostafa Kofi¹*

¹Department of Family Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
²Department of Internal Medicine, Prince Mohammed Bin Abdulaziz Hospital, Riyadh, Saudi Arabia
³Department of Internal Medicine, King Saud Medical City, Riyadh, Saudi Arabia
⁴King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

*Corresponding Author: Mostafa Kofi, Department of Family Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Received: June 06, 2023; Published: June 22, 2023

Abstract

Introduction: Worldwide obesity has become one of the most common public health concerns. In addition to being an increased mortality risk factor, it also contributes to type 2 diabetes, hypertension, heart disease, and some types of cancer. On aiming to reduce body mass index multiple measures are scientifically investigated such as lifestyle modification, pharmacological and surgical therapy. This review took a critical look on evaluating the scientific evidence of GLP-1 Vs bariatric surgery and the outcome of cardiovascular events.

Methods: PubMed, Google Scholar and Research Gate were searched for recent studies published in the period between 2010 and 2021.

Results: A total of 16 studies with 283983 patients were included in this review. Of these, 77316 patients were in the intervention groups representing 27.2% of the overall studied population. Around 9% of patients were in the bariatric surgery group, while 18% were in the GLP-1 group. Nine studies used bariatric surgery as their primary intervention, while seven used GLP-1. The mean age of participants ranged from 32.4 to 66 years.

Conclusion: In conclusion, GLP-1 showed similar event rates to the control group for MI and CVD but better stroke outcomes. Moreover, bariatric surgery, across studies demonstrated a significant reduction in the risk of the studied events. Thus, we recommend conducting high-quality trials comparing the two interventions to safely apply the results in everyday practice.

 Keywords: Bariatric Surgery; GLP-1; Obesity; Cardiovascular Events; Myocardial Infarction; Cerebrovascular Accident

References

1. Zhou X., et al. “Effects of Bariatric Surgery on Mortality, Cardiovascular Events, and Cancer Outcomes in Obese Patients: Systematic Review and Meta-analysis”. Obesity Surgery11 (2016): 2590-2601.
2. Ministry of health, Saudi guidelines on prevention and management of obesity.
3. Hung SL., et al. “The long-term risk of cardiovascular events in patients following bariatric surgery compared to a non-surgical population with obesity and the general population: a comprehensive national cohort study”. Langenbeck's Archives of Surgery 406 (2021): 189-196.
4. Romeo S., et al. “Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes”. Diabetes Care12 (2012): 2613-2617.
5. Scott JD., et al. “Does bariatric surgery reduce the risk of major cardiovascular events? A retrospective cohort study of morbidly obese surgical patients”. Surgery for Obesity and Related Diseases 1 (2013): 32-39.
6. Sjöström L., et al. “Bariatric surgery and long-term cardiovascular events”. Jama 1 (2012): 56-65.
7. Stenberg E., et al. “Association between metabolic surgery and cardiovascular outcome in patients with hypertension: A nationwide matched cohort study”. PLoS Medicine 9 (2020): e1003307.
8. Näslund E., et al. “Association of metabolic surgery with major adverse cardiovascular outcomes in patients with previous myocardial infarction and severe obesity: a nationwide cohort study”. Circulation 15 (2021): 1458-1467.
9. Douglas IJ., et al. “Bariatric surgery in the United Kingdom: a cohort study of weight loss and clinical outcomes in routine clinical care”. PLoS Medicine12 (2015): e1001925.
10. Alkharaiji M., et al. “Effect of bariatric surgery on cardiovascular events and metabolic outcomes in obese patients with insulin-treated type 2 diabetes: a retrospective cohort study”. Obesity Surgery 29 (2019): 3154-3164.
11. Pirlet C., et al. “Outcomes in patients with obesity and coronary artery disease with and without bariatric surgery”. Obesity Surgery 30 (2020): 2085-2092.
12. Marso SP., et al. “Semaglutide and cardiovascular outcomes in patients with type 2 diabetes”. New England Journal of Medicine 375 (2016): 1834-1844.
13. Marso SP., et al. “Liraglutide and cardiovascular outcomes in type 2 diabetes”. New England Journal of Medicine 4 (2016): 311-322.
14. O’Brien MJ., et al. “Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes”. JAMA Network Open8 (2018): e186125.
15. Guthrie R. “Practice pearl: liraglutide and cardiovascular and renal events in type 2”.
16. Gerstein HC., et al. “Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial”. The Lancet10193 (2019): 121-130.
17. Husain M., et al. “Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes”. New England Journal of Medicine9 (2019): 841-851.
18. Svanström H., et al. “Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden”. The lancet Diabetes and Endocrinology2 (2019): 106-114.
19. Aminian A., et al. “Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity”. JAMA 322 (2019): 1271.
20. Moussa O., et al. “Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study”. European Heart Journal 41 (2020): 2660-2667.
21. Fisher DP., et al. “Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity”. JAMA 320 (2018): 1570.
22. Liakopoulos V., et al. “Renal and Cardiovascular Outcomes After Weight Loss From Gastric Bypass Surgery in Type 2 Diabetes: Cardiorenal Risk Reductions Exceed Atherosclerotic Benefits”. Diabetes Care 43 (2020): 1276-1284.
23. Sheetz KH., et al. “Bariatric Surgery and Long-term Survival in Patients With Obesity and End-stage Kidney Disease”. JAMA Surgery 155 (2020): 581.
24. Aminian A., et al. “Bariatric surgery is associated with a lower rate of death after myocardial infarction and stroke: A nationwide study”. Diabetes, Obesity and Metabolism 21 (2019): 2058-2067.
25. “Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes”. The New England Journal of Medicine 369 (2013): 145-154.
26. Sundbom M., et al. “Substantial Decrease in Comorbidity 5 Years After Gastric Bypass”. Annals of Surgery 265 (2017): 1166-1171.
27. Falkén Y., et al. “Changes in Glucose Homeostasis after Roux-en-Y Gastric Bypass Surgery for Obesity at Day Three, Two Months, and One Year after Surgery: Role of Gut Peptides”. The Journal of Clinical Endocrinology and Metabolism 96 (2011): 2227-2235.
28. Bethel MA., et al. “Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis”. Lancet Diabetes Endocrinology 6 (2018): 105-113.
29. Hutch CR and Sandoval D. “The Role of GLP-1 in the Metabolic Success of Bariatric Surgery”. Endocrinology 158 (2017): 4139-4151.
30. Sposito AC., et al. “Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data”. Cardiovasc Diabetology 18 (2019): 23.
31. Lim S., et al. “Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns”. Trends in Endocrinology and Metabolism 29 (2018): 238-248.
32. Holman RR., et al. “Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes”. The New England Journal of Medicine 377 (2017): 1228-1239.

Citation

Citation: Mostafa Kofi., et al. “The Effect of GLP-1 on the Incidence of Cardiovascular Events Compared to Bariatric Surgery: Systematic Review”.Acta Scientific Medical Sciences 7.7 (2023): 121-131.

Copyright

Copyright: © 2023 Mostafa Kofi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.